Eevia Health Plc engages with a global market leader to evaluate collaboration on the launch of a novel dietary eye-health ingredient
Eevia Health Plc (”Eevia” or ”The Company”) is exchanging confidential information with a global market leader in eye health regarding a novel ingredient Eevia developed over the last 4 years.The counterpart is a global market leader in eye health products with EUR 4.5 billion annual turnover and a global market reach. The purpose is to evaluate collaboration on a market launch for an oral prophylactic for healthy people ‘at risk’ of developing AMD[1]. The parties will also consider an application to slow the progression for people already diagnosed with AMD.
According to WHO[2], 1.